Page 10 - Flipbook

Sacituzimab Govitecan (SG)

• Approved in mTNBC

• TROPHY-U-01 study

• Multicohort phase II study

• COHORT 1: 3 line, SG single-
rd
agent

• ORR 27%, with 77% pts having
decrease in measurable dz

• Accelerated FDA approval